1
|
Vorkapic D, Mitterer F, Pressler K, Leitner DR, Anonsen JH, Liesinger L, Mauerhofer LM, Kuehnast T, Toeglhofer M, Schulze A, Zingl FG, Feldman MF, Reidl J, Birner-Gruenberger R, Koomey M, Schild S. A Broad Spectrum Protein Glycosylation System Influences Type II Protein Secretion and Associated Phenotypes in Vibrio cholerae. Front Microbiol 2019; 10:2780. [PMID: 31849912 PMCID: PMC6901666 DOI: 10.3389/fmicb.2019.02780] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Accepted: 11/14/2019] [Indexed: 02/03/2023] Open
Abstract
Protein secretion plays a crucial role for bacterial pathogens, exemplified by facultative human-pathogen Vibrio cholerae, which secretes various proteinaceous effectors at different stages of its lifecycle. Accordingly, the identification of factors impacting on protein secretion is important to understand the bacterial pathophysiology. PglLVc, a predicted oligosaccharyltransferase of V. cholerae, has been recently shown to exhibit O-glycosylation activity with relaxed glycan specificity in an engineered Escherichia coli system. By engineering V. cholerae strains to express a defined, undecaprenyl diphosphate-linked glycoform precursor, we confirmed functional O-linked protein glycosylation activity of PglLVc in V. cholerae. We demonstrate that PglLVc is required for the glycosylation of multiple V. cholerae proteins, including periplasmic chaperones such as DegP, that are required for efficient type II-dependent secretion. Moreover, defined deletion mutants and complementation strains provided first insights into the physiological role of O-linked protein glycosylation in V. cholerae. RbmD, a protein with structural similarities to PglLVc and other established oligosaccharyltransferases (OTases), was also included in this phenotypical characterization. Remarkably, presence or absence of PglLVc and RbmD impacts the secretion of proteins via the type II secretion system (T2SS). This is highlighted by altered cholera toxin (CT) secretion, chitin utilization and biofilm formation observed in ΔpglL Vc and ΔrbmD single or double mutants. This work thus establishes a unique connection between broad spectrum O-linked protein glycosylation and the efficacy of type II-dependent protein secretion critical to the pathogen's lifecycle.
Collapse
Affiliation(s)
- Dina Vorkapic
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | - Fabian Mitterer
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | | | | | - Jan Haug Anonsen
- Centre for Ecological and Evolutionary Synthesis, Department of Biosciences, University of Oslo, Oslo, Norway
| | - Laura Liesinger
- Institute of Pathology, Medical University of Graz, Graz, Austria
- Omics Center Graz, BioTechMed-Graz, Graz, Austria
| | | | - Torben Kuehnast
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | | | - Adina Schulze
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | - Franz G. Zingl
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | - Mario F. Feldman
- Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO, United States
| | - Joachim Reidl
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
- BioTechMed-Graz, Graz, Austria
| | - Ruth Birner-Gruenberger
- Institute of Pathology, Medical University of Graz, Graz, Austria
- Omics Center Graz, BioTechMed-Graz, Graz, Austria
- Institute of Chemical Technologies and Analytics, Vienna University of Technology, Vienna, Austria
| | - Michael Koomey
- Centre for Ecological and Evolutionary Synthesis, Department of Biosciences, University of Oslo, Oslo, Norway
| | - Stefan Schild
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
- BioTechMed-Graz, Graz, Austria
| |
Collapse
|
2
|
Pressler K, Mitterer F, Vorkapic D, Reidl J, Oberer M, Schild S. Characterization of Vibrio cholerae's Extracellular Nuclease Xds. Front Microbiol 2019; 10:2057. [PMID: 31551990 PMCID: PMC6746945 DOI: 10.3389/fmicb.2019.02057] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Accepted: 08/20/2019] [Indexed: 12/22/2022] Open
Abstract
The Gram-negative bacterium Vibrio cholerae encodes two nucleases, Dns and Xds, which play a major role during the human pathogen’s lifecycle. Dns and Xds control three-dimensional biofilm formation and bacterial detachment from biofilms via degradation of extracellular DNA and thus contribute to the environmental, inter-epidemic persistence of the pathogen. During intestinal colonization the enzymes help evade the innate immune response, and therefore promote survival by mediating escape from neutrophil extracellular traps. Xds has the additional function of degrading extracellular DNA down to nucleotides, which are an important nutrient source for V. cholerae. Thus, Xds is a key enzyme for survival fitness during distinct stages of the V. cholerae lifecycle and could be a potential therapeutic target. This study provides detailed information about the enzymatic properties of Xds using purified protein in combination with a real time nuclease activity assay. The data define an optimal buffer composition for Xds activity as 50 mM Tris/HCl pH 7, 100 mM NaCl, 10 mM MgCl2, and 20 mM CaCl2. Moreover, maximal activity was observed using substrate DNA with low GC content and ambient temperatures of 20–25°C. In silico analysis and homology modeling predicted an exonuclease domain in the C-terminal part of the protein. Biochemical analyses with truncated variants and point mutants of Xds confirm that the C-terminal region is sufficient for nuclease activity. We also find that residues D787 and H837 within the predicted exonuclease domain are key to formation of the catalytic center.
Collapse
Affiliation(s)
| | - Fabian Mitterer
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | - Dina Vorkapic
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | - Joachim Reidl
- Institute of Molecular Biosciences, University of Graz, Graz, Austria.,BioTechMed-Graz, Graz, Austria
| | - Monika Oberer
- Institute of Molecular Biosciences, University of Graz, Graz, Austria.,BioTechMed-Graz, Graz, Austria
| | - Stefan Schild
- Institute of Molecular Biosciences, University of Graz, Graz, Austria.,BioTechMed-Graz, Graz, Austria
| |
Collapse
|
3
|
Pennetzdorfer N, Lembke M, Pressler K, Matson JS, Reidl J, Schild S. Regulated Proteolysis in Vibrio cholerae Allowing Rapid Adaptation to Stress Conditions. Front Cell Infect Microbiol 2019; 9:214. [PMID: 31293982 PMCID: PMC6598108 DOI: 10.3389/fcimb.2019.00214] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Accepted: 06/03/2019] [Indexed: 12/30/2022] Open
Abstract
The lifecycle of the causative agent of the severe secretory diarrheal disease cholera, Vibrio cholerae, is characterized by the transition between two dissimilar habitats, i.e., as a natural inhabitant of aquatic ecosystems and as a pathogen in the human gastrointestinal tract. Vibrio cholerae faces diverse stressors along its lifecycle, which require effective adaptation mechanisms to facilitate the survival fitness. Not surprisingly, the pathogen's transcriptome undergoes global changes during the different stages of the lifecycle. Moreover, recent evidence indicates that several of the transcription factors (i.e., ToxR, TcpP, and ToxT) and alternative sigma factors (i.e., FliA, RpoS, and RpoE) involved in transcriptional regulations along the lifecycle are controlled by regulated proteolysis. This post-translational control ensures a fast strategy by the pathogen to control cellular checkpoints and thereby rapidly respond to changing conditions. In this review, we discuss selected targets for regulated proteolysis activated by various stressors, which represent a key feature for fast adaptation of V. cholerae.
Collapse
Affiliation(s)
| | - Mareike Lembke
- Institute of Molecular Microbiology, University of Graz, Graz, Austria
| | | | - Jyl S Matson
- Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States
| | - Joachim Reidl
- Institute of Molecular Microbiology, University of Graz, Graz, Austria.,BioTechMed Graz, Graz, Austria
| | - Stefan Schild
- Institute of Molecular Microbiology, University of Graz, Graz, Austria.,BioTechMed Graz, Graz, Austria
| |
Collapse
|
4
|
Pressler K, Vorkapic D, Lichtenegger S, Malli G, Barilich BP, Cakar F, Zingl FG, Reidl J, Schild S. AAA+ proteases and their role in distinct stages along the Vibrio cholerae lifecycle. Int J Med Microbiol 2016; 306:452-62. [PMID: 27345492 DOI: 10.1016/j.ijmm.2016.05.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Revised: 05/09/2016] [Accepted: 05/24/2016] [Indexed: 12/29/2022] Open
Abstract
The facultative human pathogen Vibrio cholerae has to adapt to different environmental conditions along its lifecycle by means of transcriptional, translational and post-translational regulation. This study provides a first comprehensive analysis regarding the contribution of the cytoplasmic AAA+ proteases Lon, ClpP and HslV to distinct features of V. cholerae behaviour, including biofilm formation, motility, cholera toxin expression and colonization fitness in the mouse model. While absence of HslV did not yield to any altered phenotype compared to wildtype, absence of Lon or ClpP resulted in significantly reduced colonization in vivo. In addition, a Δlon deletion mutant showed altered biofilm formation and increased motility, which could be correlated with higher expression of V. cholerae flagella gene class IV. Concordantly, we could show by immunoblot analysis, that Lon is the main protease responsible for proteolytic control of FliA, which is required for class IV flagella gene transcription, but also downregulates virulence gene expression. FliA becomes highly sensitive to proteolytic degradation in absence of its anti-sigma factor FlgM, a scenario reported to occur during mucosal penetration due to FlgM secretion through the broken flagellum. Our results confirm that the high stability of FliA in the absence of Lon results in less cholera toxin and toxin corgulated pilus production under virulence gene inducing conditions and in the presence of a damaged flagellum. Thus, the data presented herein provide a molecular explanation on how V. cholerae can achieve full expression of virulence genes during early stages of colonization, despite FliA getting liberated from the anti-sigma factor FlgM.
Collapse
Affiliation(s)
- Katharina Pressler
- Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria
| | - Dina Vorkapic
- Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria
| | - Sabine Lichtenegger
- Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria
| | - Gerald Malli
- Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria
| | - Benjamin P Barilich
- Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria
| | - Fatih Cakar
- Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria
| | - Franz G Zingl
- Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria
| | - Joachim Reidl
- Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria
| | - Stefan Schild
- Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria.
| |
Collapse
|
5
|
Gumpenberger T, Vorkapic D, Zingl FG, Pressler K, Lackner S, Seper A, Reidl J, Schild S. Nucleoside uptake in Vibrio cholerae and its role in the transition fitness from host to environment. Mol Microbiol 2015. [PMID: 26202476 DOI: 10.1111/mmi.13143] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
As it became evident recently, extracellular DNA could be a versatile nutrient source of the facultative pathogen Vibrio cholerae along the different stages of its life cycle. By the use of two extracellular nucleases and periplasmic phosphatases, V. cholerae degrades extracellular DNA to nucleosides. In this study, we investigated the nucleoside uptake via identification and characterization of VCA0179, VC1953 and VC2352 representing the three nucleoside transport systems in V. cholerae. Based on our results VC2352 seems to be the dominant nucleoside transporter. Nevertheless, all three transporters are functional and can contribute to the utilization of nucleosides as a sole source of carbon or nitrogen. We found that the transcriptional activity of these three distal genes is equally promoted or antagonized by CRP or CytR respectively. Finally, mutants impaired for nucleoside uptake exhibit decreased transition fitness from the host into low carbon environments along the life cycle of V. cholerae.
Collapse
Affiliation(s)
- Tanja Gumpenberger
- Institute of Molecular Biosciences, University of Graz, Humboldtstr. 50, Graz, 8010, Austria
| | - Dina Vorkapic
- Institute of Molecular Biosciences, University of Graz, Humboldtstr. 50, Graz, 8010, Austria
| | - Franz G Zingl
- Institute of Molecular Biosciences, University of Graz, Humboldtstr. 50, Graz, 8010, Austria
| | - Katharina Pressler
- Institute of Molecular Biosciences, University of Graz, Humboldtstr. 50, Graz, 8010, Austria
| | - Stefanie Lackner
- Institute of Molecular Biosciences, University of Graz, Humboldtstr. 50, Graz, 8010, Austria
| | - Andrea Seper
- Institute of Molecular Biosciences, University of Graz, Humboldtstr. 50, Graz, 8010, Austria
| | - Joachim Reidl
- Institute of Molecular Biosciences, University of Graz, Humboldtstr. 50, Graz, 8010, Austria
| | - Stefan Schild
- Institute of Molecular Biosciences, University of Graz, Humboldtstr. 50, Graz, 8010, Austria
| |
Collapse
|
6
|
Benecke M, Reibe S, Baumjohann K, Gulinski S, Wetzel W, Schmidt K, Pressler K, Lebküchner I, Streckenbach M. [Morphology of low-velocity impact stains produced from single drops of blood]. Arch Kriminol 2012; 230:42-54. [PMID: 22924278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Systematic variation of blood droplet volume, the distance fallen and the surface (paper, wood, plastics, tiles) led to the conclusion that the size and the shape of the stains ("fingers", satellites) allowed to deduce the distance fallen but only if the actual surface structure was known. We found that detailed photography at the crime scene was necessary, yet experiments have to be performed due to the extreme influence of the actual surface texture on all characteristics (size, spines, peripheral spatter) of the blood stains.
Collapse
|
7
|
Pressler K. Untersuchungen am Röntgenbildverstärker bei chronischer Appendizitis*. ROFO-FORTSCHR RONTG 2009. [DOI: 10.1055/s-0029-1213033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Weh L, Dahmen G, Gärtner T, Pressler K, Algermissen O. Die pathogene Relevanz der Plika parapatellaris medialis. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1051145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Brugger W, Dierkesmann R, Toomes H, Engelhardt R, Hasse J, Pressler K, Kollmannsberger C, Schumacher M, Frommhold H, Bamberg M, Kanz L. Multicenter Randomized Phase III Study Evaluating the Role of High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Support in Patients with Limited-Stage Small-Cell Lung Cancer. Oncol Res Treat 1998. [DOI: 10.1159/000054963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
10
|
Brugger W, Fetscher S, Hasse J, Frommhold H, Pressler K, Mertelsmann R, Engelhardt R, Kanz L. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin Oncol 1998; 25:42-8. [PMID: 9535211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Combined-modality treatment for limited-disease small cell lung cancer using conventional chemotherapy and chest irradiation achieves high response rates, but most patients relapse over a period of 12 to 16 months. To improve current results, we performed a phase II trial including high-dose chemotherapy and peripheral blood progenitor cell transplantation (PBPCT) as part of an early intensification strategy after two cycles of induction therapy. Moreover, to reduce the risk of local recurrence, the protocol included surgical resection in stages I to IIIA patients as well as chest irradiation. Between January 1991 and July 1994, 16 consecutive patients (median age, 50 years; age range, 30 to 59 years) were treated in this single-center trial. The patients received two cycles of conventional chemotherapy consisting of etoposide 500 mg/m2, ifosfamide 4 g/m2, cisplatin 50 mg/m2, and epirubicin 50 mg/m2 plus granulocyte colony-stimulating factor 5 microg/kg at a 3-week interval, followed by PBPC collection and subsequent high-dose etoposide 1,500 mg/m2, ifosfamide 12 g/m2, carboplatin 750 mg/m2, and epirubicin 150 mg/m2 with PBPCT. The duration of the entire chemotherapy program was 9 weeks. Six of 10 patients in stages I to IIIA and one of six patients in stage IIIB received neoadjuvant or adjuvant surgery before high-dose chemotherapy, followed by thoracic (50 Gy) and prophylactic (30 Gy) cranial irradiation. Hematopoietic reconstitution after high-dose chemotherapy occurred within 11 days (range, 9 to 17 days) for both neutrophils (>0.5 x 10(9)/L) and platelets (>20 x 10(9)/L). Oral mucositis (World Health Organization grade 2 to 4) was the predominant nonhematologic toxicity, which was observed in 12 of 16 patients. One patient developed neutropenic septicemia with fatal multiorgan failure. At a median follow-up of 44 months (range, 32 to 77 months) after PBPCT, nine patients are alive and well, resulting in a disease-free and overall survival rate of 56.3% +/- 12.4%. The median overall survival has not yet been achieved. None of the patients who had surgery relapsed or died after therapy. All relapses occurred within the first 12 months after PBPCT. Patients in stages I to IIIA (10 patients) had a 70% +/- 14% overall survival rate at 4 years, while patients in stage IIIB (six patients) had a 33% +/- 19% survival rate at 4 years, with a median survival of 17 months posttransplant. These data demonstrate that a multimodality treatment including early high-dose chemotherapy with PBPCT may lead to a prolonged disease-free survival in the majority of patients. A randomized phase III study has now been initiated to prospectively investigate the role of high-dose chemotherapy, surgery, and chest irradiation in the multidisciplinary approach to limited-disease small cell lung cancer.
Collapse
Affiliation(s)
- W Brugger
- Department of Hematology/Oncology, Albert-Ludwigs University, Freiburg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer. Semin Oncol 1995; 22:3-8. [PMID: 7531368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Conventional-dose chemotherapy for limited-disease small cell lung cancer has resulted in high response rates, but rarely in a cure. In an ongoing phase I-II trial, limited-disease small cell lung cancer patients received high-dose chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation as part of an early intensification strategy after two cycles of induction chemotherapy. Eligible patients (n = 18) were initially treated with two cycles of etoposide (500 mg/m2), ifosfamide (4 g/m2), cisplatin (50 mg/m2), epirubicin (50 mg/m2) and granulocyte colony-stimulating factor to combine an effective, standard-dose chemotherapy regimen with simultaneous mobilization of PBPCs. Patients who were in partial remission or complete remission after two cycles of induction chemotherapy received high-dose intensification chemotherapy with cumulative doses of 1,500 mg/m2 etoposide, 12 g/m2 ifosfamide, 750 mg/m2 carboplatin, and 150 mg/m2 epirubicin, followed by autologous PBPC transplantation and granulocyte colony-stimulating factor. The duration of the complete chemotherapy program was 9 weeks. All patients received chest irradiation posttransplantation (50 Gy), and those in complete remission received additional prophylactic cranial irradiation (30 Gy). To date, 13 patients with a median age of 49 years (age range, 34 to 62 years) have been treated within this combined-modality treatment protocol. At a median follow-up of 14 months (range, 3 to 45 months) after transplantation, 11 patients were alive and nine were still in complete remission. Nonhematologic toxicity was acceptable; World Health Organization grades 2 to 4 oral mucositis was the most frequently observed (85%) adverse event. No toxic deaths were observed, and hematopoietic reconstitution occurred rapidly after PBPC transplantation; platelet transfusion independence (> 20,000 microL) and neutrophil counts greater than 500 microL were observed at study day 12+. The median survival time was not yet reached. These preliminary data demonstrate that early, high-dose chemotherapy and PBPC transplantation followed by local radiotherapy is safe and may lead to prolonged disease-free survival in some patients. Prospective, randomized studies in a larger series of patients will be required to provide definitive proof of the role of early high-dose chemotherapy in the management of limited-disease small cell lung cancer.
Collapse
Affiliation(s)
- W Brugger
- Department of Hematology/Oncology and Radiation Oncology, Albert-Ludwigs University Medical Center, Freiburg, Germany
| | | | | | | | | |
Collapse
|
12
|
Brugger W, Birken R, Bertz H, Hecht T, Pressler K, Frisch J, Schulz G, Mertelsmann R, Kanz L. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol 1993; 84:402-7. [PMID: 7692928 DOI: 10.1111/j.1365-2141.1993.tb03093.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We report on the chemotherapy plus granulocyte colony-stimulating factor (G-CSF) induced mobilization of peripheral blood progenitor cells (PBPCs) and their impact on haematopoietic recovery following high-dose chemotherapy. Twenty-four patients with advanced solid tumours or lymphomas received standard-dose chemotherapy with VP16, ifosfamide and cisplatin (VIP) followed by filgrastim (G-CSF; 5 micrograms/kg s.c. daily for 14 d) for the prevention of chemotherapy induced neutropenia and for the simultaneous mobilization of PBPCs. Maximal numbers of progenitors of different lineages were reached at day 11 (range 9-14) after VIP chemotherapy. A median of 0.415 x 10(9)/l CD34+ cells (range 0.11-1.98), 9000 CFU-GM/ml (range 2800-17,700), 3500 BFU-E/ml (range 400-10,800) and 200 CFU-GEMM/ml (range 0-4400) were recruited. One single apheresis yielded a median of 1.6 x 10(8) mononuclear cells/kg (range 0.2-5.4) or 5.4 x 10(6) CD34+ cells/kg body weight (range 0.2-24.2). Fourteen patients who showed at least a partial remission after two cycles of the standard-dose chemotherapy regimen were subjected to high-dose VIP chemotherapy (cumulative doses of 1500 mg/m2 VP16, 12 g/m2 ifosfamide and 150 mg/m2 cisplatin) with or without PBPC support. The first six patients were treated with growth factors only (IL-3/GM-CSF) and did not receive PBPCs, whereas the following eight patients were supported with PBPCs in addition to IL-3 and GM-CSF. Neutrophil recovery as well as platelet recovery were significantly faster in patients receiving PBPCs with a median of 6.5 d below 0.1 x 10(9) neutrophils/l and 3 d below 20 x 10(9) platelets/l as compared to 10.5 d and 8 d in control patients receiving growth factors only. The accelerated platelet recovery in patients supported with PBPCs might be explained--in the absence of detectable colony-forming units megakaryocyte--by the presence of glycoprotein IIb/IIIa+, non-proliferating endomitotic megakaryocytic precursor cells within G-CSF mobilized PBPCs. Our data demonstrate that chemotherapy plus G-CSF mobilized PBPCs accelerate both neutrophil and platelet recovery after high-dose VIP chemotherapy in patients with solid tumours or lymphomas.
Collapse
Affiliation(s)
- W Brugger
- Albert-Ludwigs-University Medical Centre, Department of Haematology and Oncology, Freiburg, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 1992; 10:1452-9. [PMID: 1517788 DOI: 10.1200/jco.1992.10.9.1452] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
PURPOSE To combine the benefits of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on neutrophil recovery and recombinant human interleukin-3 (rhIL-3) on platelet recovery, we applied standard-dose chemotherapy with the combined administration of IL-3 and GM-CSF to investigate their efficacy and toxicity. PATIENTS AND METHODS Thirty-six patients with advanced malignancies were treated with etoposide (VP16) 500 mg/m2, ifosfamide 4 g/m2, and cisplatin 50 mg/m2 (VIP), followed by the sequential administration of IL-3 (days 1 to 5 subcutaneously [SC]) and GM-CSF (day 6 to 15 SC). Control patients received GM-CSF alone or were treated without hematopoietic growth factors. RESULTS Subcutaneous IL-3 and GM-CSF treatment was well tolerated; low-grade fever (World Health Organization grade 1 to 2) was the only consistent clinical symptom. Neutrophil recovery documented that the duration of neutropenia less than 0.1 x 10(9)/L or less than 0.5 x 10(9)/L was identical in GM-CSF as well as IL-3 and GM-CSF-treated patients, but was shortened significantly when compared with patients who were treated without cytokines. Overall platelet recovery was not different significantly in the three treatment groups. The biologic activity of IL-3 in this cytokine combination was reflected in a variety of effects, which included an increase in basophil and eosinophil counts and the induction of circulating hematopoietic progenitor cells. CONCLUSION We conclude that after conventional-dose VIP chemotherapy, a shortened treatment course of IL-3 (5 days) sequentially followed by GM-CSF (10 days) combines the benefits of prolonged single GM-CSF treatment on WBC count recovery in all patients and an accelerated platelet recovery only in some intensively pretreated patients.
Collapse
Affiliation(s)
- W Brugger
- Department of Medicine I, Albert-Ludwigs-University Medical Center, Freiburg, Germany
| | | | | | | | | | | |
Collapse
|
14
|
Sarateanu DE, Ehrengut W, Pressler K, Peukert M, Schenk KD. Serological response to whole, split and subunit influenza vaccines of persons with and without immunological experience towards influenza A/U.S.S.R. 90/77 virus. Comp Immunol Microbiol Infect Dis 1980; 3:225-36. [PMID: 7471712 DOI: 10.1016/0147-9571(80)90061-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
15
|
Pressler K, Schenk D. [Antibodies against A/USSR/90/77 (H1N1) following vaccination with A/New Jersey/76 (Hsw 1 N1)-vaccine]. MMW Munch Med Wochenschr 1978; 120:116. [PMID: 304967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
16
|
Pressler K. [Influenza immunity]. Med Monatsschr 1976; 30:256. [PMID: 967111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
17
|
Potel J, Pressler K, Ruwisch KH. [The influence of chemical immunosuppression on the protective efficacy of vaccinations (author's transl)]. Zentralbl Bakteriol Orig A 1973; 225:416-23. [PMID: 4150077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
18
|
Pressler K. [Serological studies following immunization against horse influenza. 3. Reimmunization two years following first vaccination and antibody level during an interval of three years]. Zentralbl Veterinarmed B 1972; 19:426-33. [PMID: 5051224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
19
|
Pressler K. [Serologic studies following influenza immunization of horses. II. Reimmunization 1 year after the initial vaccination]. Zentralbl Veterinarmed B 1970; 17:1003-9. [PMID: 5498582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
20
|
Bezold K, Feindt HR, Pressler K. Der Röntgenbildverstärker im Routinebetrieb. ROFO-FORTSCHR RONTG 1956. [DOI: 10.1055/s-0029-1213019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Pressler K. Thrombosiertes Aneurysma der Aorta abdominalis. ROFO-FORTSCHR RONTG 1956. [DOI: 10.1055/s-0029-1212861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Pressler K. Der Füllungsmechanismus der gesunden Appendix *. ROFO-FORTSCHR RONTG 1955. [DOI: 10.1055/s-0029-1212711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|